Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Preoperative Fasting Duration and Gastric Residue in Pediatric Upper Gastrointestinal Endoscopy

22 maj 2026 uppdaterad av: Gürcan Güler, Bursa Sevket Yilmaz Training and Research Hospital

Evaluation of Preoperative Fasting Duration and Gastric Residue in Children Undergoing Upper Gastrointestinal Endoscopy for Gastrointestinal Symptoms or Pathology

This retrospective observational study aims to evaluate the relationship between preoperative fasting duration and gastric residue in pediatric patients undergoing upper gastrointestinal endoscopy for gastrointestinal symptoms or pathology. The study will assess the associations between gastric residue, gastrointestinal symptoms, underlying gastrointestinal diseases, and endoscopic findings. Data will be retrospectively collected from hospital records, anesthesia records, and endoscopy reports to investigate whether prolonged fasting duration reliably predicts an empty stomach in pediatric gastrointestinal patients.

Studieöversikt

Status

Har inte rekryterat ännu

Detaljerad beskrivning

Pulmonary aspiration is one of the most feared complications in pediatric anesthesia, and preoperative fasting is routinely used to reduce gastric content and aspiration risk. Current pediatric fasting guidelines support more liberal fasting regimens, especially for clear liquids, in order to avoid unnecessary prolonged fasting. However, prolonged fasting duration does not always guarantee an empty stomach, particularly in pediatric patients with gastrointestinal symptoms or underlying gastrointestinal pathology.

Recent studies evaluating gastric contents in children have mainly focused on gastric ultrasonography and estimated gastric volume in healthy pediatric populations. Data regarding directly observed gastric residue during upper gastrointestinal endoscopy in pediatric gastrointestinal patients remain limited.

This retrospective observational single-center study will include pediatric patients who underwent upper gastrointestinal endoscopy for gastrointestinal symptoms or pathology between January 2025 and April 2026. Data will be retrospectively obtained from hospital information systems, anesthesia records, electronic medical records, and endoscopy reports.

Demographic characteristics, gastrointestinal symptoms, underlying gastrointestinal diseases, medication use, endoscopic findings, preoperative fasting duration, and endoscopically observed gastric residue will be evaluated. Gastric residue severity will be categorized as none, mild, moderate, or severe. In addition, clinically relevant residue will be defined as moderate or severe gastric residue.

The primary objective of the study is to evaluate the relationship between preoperative fasting duration and gastric residue severity. Secondary analyses will assess factors associated with clinically relevant gastric residue, including gastrointestinal inflammatory disease and other clinical variables.

The findings of this study may contribute to a better understanding of gastric residue patterns in pediatric gastrointestinal patients and support more individualized perioperative fasting assessment approaches.

Studietyp

Observationell

Inskrivning (Beräknad)

110

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Bursa
      • Yıldırım, Bursa, Turkiet (Türkiye), 16310
        • University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Pediatric patients undergoing upper gastrointestinal endoscopy for evaluation of gastrointestinal symptoms or suspected gastrointestinal pathology at a single tertiary care center will be included in this retrospective observational study. The study population will consist of patients evaluated between January 2025 and April 2026. Data will be retrospectively obtained from hospital information systems, anesthesia records, electronic medical records, and endoscopy reports. The study will evaluate demographic characteristics, gastrointestinal symptoms, preoperative fasting duration, endoscopic findings, underlying gastrointestinal diseases, medication use, and endoscopically observed gastric residue.

Beskrivning

Inclusion Criteria:

  • Pediatric patients aged under 18 years
  • Patients who underwent upper gastrointestinal endoscopy for gastrointestinal symptoms or pathology
  • Patients with available hospital records, anesthesia records, and endoscopy reports
  • Patients with documented preoperative fasting duration
  • Patients with documented endoscopic assessment of gastric residue

Exclusion Criteria:

  • Patients aged 18 years or older
  • Patients with missing or incomplete data for key study variables
  • Patients without documented preoperative fasting duration
  • Patients without documented gastric residue assessment during endoscopy
  • Duplicate endoscopy records from the same patient, if only the first eligible procedure is included

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Pediatric Upper Gastrointestinal Endoscopy Cohort
Pediatric patients undergoing upper gastrointestinal endoscopy for gastrointestinal symptoms or pathology will be included in this retrospective observational cohort. Data regarding demographic characteristics, gastrointestinal symptoms, preoperative fasting duration, endoscopic findings, underlying gastrointestinal diseases, medication use, and endoscopically observed gastric residue will be retrospectively evaluated using hospital records, anesthesia records, and endoscopy reports. Gastric residue severity will be categorized as none, mild, moderate, or severe.
Upper gastrointestinal endoscopy performed for evaluation of gastrointestinal symptoms or pathology in pediatric patients. The procedure was conducted under sedation or anesthesia according to institutional clinical practice. Endoscopic findings and endoscopically observed gastric residue were retrospectively evaluated from medical records and endoscopy reports.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Gastric Residue Severity
Tidsram: At the time of upper gastrointestinal endoscopy
Severity of endoscopically observed gastric residue during upper gastrointestinal endoscopy, categorized as none, mild, moderate, or severe according to endoscopic findings documented in medical records and endoscopy reports.
At the time of upper gastrointestinal endoscopy

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Clinically Relevant Gastric Residue
Tidsram: At the time of upper gastrointestinal endoscopy
Presence of clinically relevant gastric residue during upper gastrointestinal endoscopy, defined as moderate or severe gastric residue based on endoscopic observation documented in medical and endoscopy records.
At the time of upper gastrointestinal endoscopy

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juni 2026

Primärt slutförande (Beräknad)

1 juli 2026

Avslutad studie (Beräknad)

1 juli 2026

Studieregistreringsdatum

Först inskickad

22 maj 2026

Först inskickad som uppfyllde QC-kriterierna

22 maj 2026

Första postat (Faktisk)

29 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

22 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data will not be publicly shared because the study involves retrospective review of pediatric patient records and contains potentially sensitive clinical information.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera